2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Bevacizumab

Bevacizumab  (Synonyms: Anti-Human VEGF, Humanized Antibody)

Cat. No.: HY-P9906 Purity: 98.90%
COA
SDS
Technical Support

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

For research use only. We do not sell to patients.

CAS No. : 216974-75-3

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 51 publication(s) in Google Scholar

Other Forms of Bevacizumab:

Bevacizumab Related Antibodies

Top Publications Citing Use of Products

51 Publications Citing Use of MCE Bevacizumab

IHC
WB
In Vivo Efficacy Study
Cell Migration/Invasion Assay
IF
Others
Flow Cytometry

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417.  [Abstract]

    Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096.  [Abstract]

    Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096.  [Abstract]

    Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45+ cells), anti-CD68/CD80-stained macrophages (gated on CD45+ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45+ Lin-1- T cells), and anti-CD3/CD8-stained T cells (gated on CD45+ cells) in tumor tissues after different treatments (n = 5 independent mice).

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069.  [Abstract]

    Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069.  [Abstract]

    Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2024 Oct 30:JCO2401266.  [Abstract]

    Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798.  [Abstract]

    Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798.  [Abstract]

    Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638.  [Abstract]

    VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.

    View All VEGFR Isoform Specific Products:

    View All Isoforms
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    VEGFA
    In Vitro

    Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Bevacizumab Related Antibodies
    In Vivo

    It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Gene ID

    7422  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    146.56 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Bevacizumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Flow cytometric analysis of 1X106 Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
    • Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.
    Purity & Documentation

    Purity: ≥99.0%

    SDS (252 KB)

    COA (291 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    Cell Assay
    [2]

    Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2][3]

    Rats[2]
    After modeling, ninety rats are randomly divided into five groups (eighteen rats per group) and receive a subconjunctival injection with 0.05 mL per rat of (1) 0.9% NaCl, (2) solvent, (3) 25 mg/mL Bevacizumab and (4) 25 mg/mL FD006 in the superior temporal conjunctiva on the day after modeling. All chemical burns and treatments are performed by one investigator. The operator is blinded to the treatment group from which each cornea is derived. At postoperative days 3, 7, 14, 21 and 28, the eyes are harvested for further studies after the rats are sacrificed.
    Mice[3]
    Five-week-old Balb/cAnNCrlBR athymic (nu+/nu+) mice are injected into the fourth mammary fat pad with MDA-MB-468 cells (107 cells per mice) resuspended in 200 μL of Matrigel. Seven days after the tumor cell injection, tumor-bearing mice are randomly assigned (n=10 per group) to receive the following: NVP-LDE225 20 mg/kg per os every day for 4 weeks; Bevacizumab 5 mg/kg intravenously (i.v.), twice a week for 4 weeks. Tumor diameter is assessed with a vernier caliper, and tumor volume (cm3) is measured.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Bevacizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Bevacizumab216974-75-3Anti-Human VEGF, Humanized AntibodyVEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Bevacizumab
    Cat. No.:
    HY-P9906
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.